Funded Biotechnology Startups in Emeryville
Emeryville's biotech funding record spans a wide range of stages and deal sizes, from Injectsense's $3M raise in November 2023 to Amyris's $400M post-IPO d…
Emeryville's biotech funding record spans a wide range of stages and deal sizes, from Injectsense's $3M raise in November 2023 to Amyris's $400M post-IPO debt round in November 2021. The 17 rounds shown here include both early venture activity — Aralez Bio's $12M Series A in October 2024, Slingshot Biosciences' $11M Series A in February 2023 — and substantial late-stage capital deployment: Nutcracker Therapeutics closed a $167M Series C in March 2022, and 4D Molecular Therapeutics raised $120M in May 2023. Three companies (Amyris, Lucira Health, NovaBay Pharmaceuticals) appear with post-IPO rounds, reflecting a layer of publicly traded firms that continue to access private and debt markets from the same Emeryville address.
Funding activity has carried into 2025, with Ansa Biotechnologies closing a $45M Series B in October and two additional rounds recorded in August. The majority of rounds carry a "Series Unknown" classification, which is common in this geography where biotech companies often structure non-standard tranches or raise without publicizing round labels.
Most recent rounds
17 shownRelated listings
Frequently asked
What are the largest disclosed rounds among Emeryville biotech companies in this dataset?
The four largest are Amyris at $400M (post-IPO debt, November 2021), Nutcracker Therapeutics at $167M (Series C, March 2022), 4D Molecular Therapeutics at $120M (May 2023), and Lucira Health at $80M (post-IPO debt, February 2022). All four represent late-stage or post-public capital raises, not early venture rounds.
How recent is the funding activity shown here?
The three most recent rounds are Ansa Biotechnologies' $45M Series B (October 2025), Bolt's $4M raise (August 14, 2025), and Geltor's undisclosed round (August 7, 2025). Activity spans back to March 2020, with a visible concentration of deals in 2022 and 2023.
Are any of the companies in this list already publicly traded?
Three rounds in the dataset are classified as post-IPO: Amyris and Lucira Health both raised post-IPO debt (in 2021 and 2022 respectively), and NovaBay Pharmaceuticals closed a $5M post-IPO equity round in September 2022. This indicates a subset of Emeryville biotech has reached public markets but continues to raise external capital.
Does any company appear more than once in the data?
Eureka Therapeutics appears twice: an unlabeled $45M round in March 2020 and a $11M round in June 2023. The recurrence suggests the company has raised across multiple cycles within the same Emeryville base.
What early-stage activity is visible in this dataset?
Two Series A rounds appear: Aralez Bio raised $12M in October 2024 and Slingshot Biosciences raised $11M in February 2023. The single Series B is Ansa Biotechnologies' $45M close in October 2025, making named early-stage rounds a minority of the 17 shown — many are classified as Series Unknown.
What is the range of deal sizes across the disclosed rounds?
Disclosed amounts run from $3M (Injectsense, November 2023) to $400M (Amyris, November 2021). Two rounds — Geltor (August 2025) and MycoWorks (October 2022) — list undisclosed amounts, so the full range may be wider.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.